Three recent studies have confirmed the potential use of the ReCell ‘spray-on skin’ system to treat multiple dermatological conditions.
One study found combining ReCell (Avita Medical’s autologous cell harvesting device) with dermabrasion to treat facial acne scars more than halved average healing time.
The data published in Aesthetic Plastic Surgery by China’s Department of Plastic Surgery at Peking Union Medical College Hospital analysed healing time and rate of post-operative complications in 78 patients with acne scars treated using dermabrasion with and without the ReCell system.
Acne scars treated using dermabrasion with ReCell healed more quickly on average (5.27 ± 1.086 days) than without ReCell (average healing time 12.30 ± 1.725 days). In addition, there were no post-operative complications, such as pigmentation and scar hyperplasia, and higher patient satisfaction rates for those treated with ReCell.
A second study published in the Journal Of Dermatological Treatment by researchers from China’s Guangzhou New Centre Institute of Vitiligo and Dongguan Eighth People’s Hospital examined “the clinical efficacy of treatment using the autologous non-cultured epidermal cell suspension technique (NCES) for stable vitiligo in 41 patients”.
Vitiligo is an acquired depigmentation skin disorder mainly caused by the destruction of melanocytes.
After 6-9 months of follow-up, 80.5% (33/41) of patients showed good response; among these patients, 17.1% (7/41) showed complete or almost complete repigmentation.
Interestingly, all 4 children showed very good response (more than 76% repigmentation).
There were “no significant differences in the efficacy of treatment between the different transplantation areas of the facial neck, trunk and distal limbs, and there were no adverse effects such as infection or scar formation”.
The researchers concluded: “Our study shows that the NCES technique has a high therapeutic effect, is safe for patients with stable vitiligo, and may be a very promising potential option for treating children.”
A third study published in the Journal Of Cosmetic Dermatology by China’s Department of Dermatology at Huashan Hospital and Fudan University in Shanghai examined “the use of non-cultured regenerative epithelial suspension for improving skin colour and scars: a report of 8 cases and review of the literature”.
The study found “8 patients including vitiligo vulgaris, postburn reconstruction, acne scars, and congenital melanocytic nevi treated by ReCell technology combined with microdermabrasion showed significant improvement in skin texture and color. And 17 studies of the research on ReCell technology were totally included in the systematic review.”
It concluded: “Our investigation showed that Regenerative Epithelial Suspension gained by ReCell technology combined with microdermabrasion may improve scar and depigmentation diseases.”
Avita Medical is a regenerative medicine company focused on development and commercialisation of innovative therapies leveraging the healing properties of a patient’s own skin.
The ReCell System, which uses a small amount of a patient’s own skin to prepare spray-on skin cells at the point of care, is currently approved by the US Food and Drug Administration for the treatment of acute thermal burns in patients 18 years and older. In international markets, it is approved to promote skin healing in a wide range of applications including burns, acute and chronic wounds, scars and vitiligo.
Avita Medical’s Chief Technology Officer Andrew Quick commented: “It’s exciting to see physicians worldwide interested in studying the possible application of the ReCell System to advance patient care across a broad range of treatments. We look forward to continued collaboration within the global medical community as we explore the full potential of this regenerative technology platform to address unmet medical needs.”
Sources: Aesthetic Plastic Surgery, Journal Of Cosmetic Dermatology, Journal Of Dermatological Treatment and www.businesswire.com
